

UGANDA

Number of new cases

35 968

Number of deaths

24 629

Number of prevalent cases (5-year)

77 028


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	23 898 167	24 534 706	48 432 873
Incidence*			
Number of new cancer cases	15 459	20 509	35 968
Age-standardized incidence rate	156.2	157.7	154.4
Risk of developing cancer before the age of 75 years (cum. risk %)	16.2	15.7	15.8
Top 3 leading cancers (ranked by cases)**	Prostate Kaposi sarcoma Oesophagus	Cervix uteri Breast Kaposi sarcoma	Cervix uteri Kaposi sarcoma Breast
Mortality*			
Number of cancer deaths	10 708	13 921	24 629
Age-standardized mortality rate	116.3	115.5	113.9
Risk of dying from cancer before the age of 75 years (cum. risk %)	12.1	12.2	12.0
Top 3 leading cancers (ranked by deaths)**	Prostate Kaposi sarcoma Oesophagus	Cervix uteri Breast Oesophagus	Cervix uteri Oesophagus Kaposi sarcoma
Prevalence*			
5-year prevalent cases	31 110	45 918	77 028




Top 5 most frequent cancers**


Males



Females



Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Prostate	2 699	17.5%
2nd	Kaposi sarcoma	2 689	17.4%
3rd	Oesophagus	1 483	9.6%
4th	NHL	1 266	8.2%
5th	Liver	1 130	7.3%
-	Others	6 192	40.1%

Number of new cases in 2022, males, all ages

Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	6 938	33.8%
2nd	Breast	2 999	14.6%
3rd	Kaposi sarcoma	1 358	6.6%
4th	NHL	1 003	4.9%
5th	Oesophagus	955	4.7%
-	Others	7 256	35.4%

Number of new cases in 2022, females, all ages

Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	6 938	19.3%
2nd	Kaposi sarcoma	4 047	11.3%
3rd	Breast	2 999	8.3%
4th	Prostate	2 699	7.5%
5th	Oesophagus	2 438	6.8%
-	Others	16 847	46.8%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Cervix uteri	6 938	1	19.3	5.7	4 782	1	19.4	4.6	16 453	21.4
Kaposi sarcoma	4 047	2	11.3	0.98	2 238	3	9.1	0.56	8 347	10.8
Breast	2 999	3	8.3	2.5	1 560	5	6.3	1.4	7 010	9.1
Prostate	2 699	4	7.5	5.3	1 554	6	6.3	2.9	4 788	6.2
Oesophagus	2 438	5	6.8	1.6	2 332	2	9.5	1.5	3 919	5.1
NHL	2 269	6	6.3	0.71	1 492	7	6.1	0.56	5 714	7.4
Liver	1 963	7	5.5	0.99	1 833	4	7.4	0.95	3 203	4.2
Colorectum	1 394	8	3.9	0.89	1 013	8	4.1	0.66	3 000	3.9
Leukaemia	806	9	2.2	0.23	590	9	2.4	0.21	1 923	2.5
Ovary	720	10	2.0	0.62	509	10	2.1	0.52	1 613	2.1
Stomach	608	11	1.7	0.38	508	11	2.1	0.33	972	1.3
Lung	562	12	1.6	0.34	480	12	1.9	0.32	910	1.2
Nasopharynx	537	13	1.5	0.23	378	14	1.5	0.19	1 298	1.7
Kidney	503	14	1.4	0.11	372	15	1.5	0.12	1 287	1.7
Brain CNS	462	15	1.3	0.19	403	13	1.6	0.19	1 251	1.6
Lip, oral cavity	458	16	1.3	0.25	293	16	1.2	0.18	995	1.3
Hodgkin lymphoma	392	17	1.1	0.11	189	18	0.77	0.07	1 052	1.4
Corpus uteri	391	18	1.1	0.47	133	24	0.54	0.17	1 003	1.3
Thyroid	357	19	0.99	0.18	138	23	0.56	0.09	815	1.1
Bladder	326	20	0.91	0.20	189	18	0.77	0.11	737	0.96
Penis	316	21	0.88	0.35	146	22	0.59	0.16	754	0.98
Pancreas	290	22	0.81	0.20	271	17	1.1	0.19	367	0.48
Larynx	243	23	0.68	0.17	166	21	0.67	0.12	590	0.77
Multiple myeloma	188	24	0.52	0.12	169	20	0.69	0.12	400	0.52
Melanoma	156	25	0.43	0.08	59	28	0.24	0.03	401	0.52
Vulva	143	26	0.40	0.12	95	25	0.39	0.07	371	0.48
Oropharynx	107	27	0.30	0.06	75	26	0.31	0.05	221	0.29
Salivary glands	93	28	0.26	0.04	65	27	0.26	0.03	213	0.28
Hypopharynx	73	29	0.20	0.06	55	29	0.22	0.05	91	0.12
Testis	63	30	0.18	0.05	26	32	0.11	0.03	174	0.23
Vagina	43	31	0.12	0.03	23	33	0.09	0.02	81	0.11
Mesothelioma	33	32	0.09	0.01	32	30	0.13	0.01	55	0.07
All cancers	35 968	-	-	15.8	24 629	-	-	12.0	77 028	-
All cancers excl. NMSC	35 539	-	-	15.6	24 440	-	-	11.9	75 906	-

Data source and methods

Incidence



Country-specific data source: Kyadondo County cancer registry, Gulu cancer registry
Method: Weighted/simple average of the most recent sub-national rates applied to 2022 population

Mortality

Country-specific data source: No data
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-; site- and age-specific incidence to 1-;3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)
 ** NMSC included in other cancers
 Age standardization using world population ([see link](#))

References

Website citation
 Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

